Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
WEB2 days ago · The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. ... the news and media division of Thomson Reuters, is ...
Obesity drug developer BioAge seeks up to $587 million valuation in US IPO
WEB1 day ago · The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. Sofinnova Venture Partners currently has a 7.3% ...
Obesity drug developer BioAge sets IPO terms (Pending:BIOA)
WEB1 day ago · Obesity drug developer BioAge Labs has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the ...
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
WEBObesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at ...
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
WEB2 days ago · September 18, 2024 at 4:53 PM EDT. Save. BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 ...
Obesity drugmaker BioAge targets $158 million in IPO
WEB2 days ago · Obesity drugmaker BioAge targets $158 million in IPO BY David Morris and Bloomberg The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday.
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
WEBBioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement. The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday with the US Securities and Exchange Commission.
BioAge Labs Files For $100M IPO, Becomes The New Entrant In …
WEBSep 4, 2024 · BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering.
Eli Lilly partner BioAge files for US IPO | Reuters
WEBSept 3 (Reuters) - BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly (LLY.N), filed for an initial public offering in the United States on Tuesday as it...
BioAge Labs Files for IPO to Be Led by Goldman, Morgan Stanley
WEBSep 3, 2024 · BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, has filed for an initial public offering.
- Some results have been removed
Skip to content